{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Koca D"],"funding":["Grenoble Alpes University","Grenoble Graduate School in Chemistry, Biology, and Health","University of Grenoble Alpes, the Commissariat à l’Energie Atomique et aux Energies Alternatives (CEA), and the Institut National de la Santé et de la Recherche Médicale (Inserm)"],"pagination":["2701"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC10216355"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["15(10)"],"pubmed_abstract":["Clear-cell renal cell carcinoma (ccRCC) accounts for 75% of kidney cancers. Due to the high recurrence rate and treatment options that come with high costs and potential side effects, a correct prognosis of patient survival is essential for the successful and effective treatment of patients. Novel biomarkers could play an important role in the assessment of the overall survival of patients. COL7A1 encodes for collagen type VII, a constituent of the basal membrane. COL7A1 is associated with survival in many cancers; however, the prognostic value of COL7A1 expression as a standalone biomarker in ccRCC has not been investigated. With five publicly available independent cohorts, we used Kaplan-Meier curves and the Cox proportional hazards model to investigate the prognostic value of COL7A1, as"],"journal":["Cancers"],"pubmed_title":["COL7A1 Expression Improves Prognosis Prediction for Patients with Clear Cell Renal Cell Carcinoma Atop of Stage."],"pmcid":["PMC10216355"],"funding_grant_id":["ANR-10-LABX-49-01","ANR-17-EURE-0003"],"pubmed_authors":["Koca D","Filhol O","Jardillier R","Cochet C","Guyon L","Seraudie I"],"additional_accession":[]},"is_claimable":false,"name":"COL7A1 Expression Improves Prognosis Prediction for Patients with Clear Cell Renal Cell Carcinoma Atop of Stage.","description":"Clear-cell renal cell carcinoma (ccRCC) accounts for 75% of kidney cancers. Due to the high recurrence rate and treatment options that come with high costs and potential side effects, a correct prognosis of patient survival is essential for the successful and effective treatment of patients. Novel biomarkers could play an important role in the assessment of the overall survival of patients. COL7A1 encodes for collagen type VII, a constituent of the basal membrane. COL7A1 is associated with survival in many cancers; however, the prognostic value of COL7A1 expression as a standalone biomarker in ccRCC has not been investigated. With five publicly available independent cohorts, we used Kaplan-Meier curves and the Cox proportional hazards model to investigate the prognostic value of COL7A1, as","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 May","modification":"2026-06-27T03:18:33.021Z","creation":"2025-04-04T20:56:44.313Z"},"accession":"S-EPMC10216355","cross_references":{"pubmed":["37345040"],"doi":["10.3390/cancers15102701"]}}